<DOC>
	<DOCNO>NCT00994682</DOCNO>
	<brief_summary>Obesity Type 2 diabetes create silent epidemic , Non-alcoholic fatty liver disease , chronic liver disease associate insulin resistance , impair glucose intolerance , hepatic fat accumulation . The thiazolidinedione pioglitazone improve glucose/lipid metabolism histology NASH improve insulin resistance liver/peripheral/adipose tissue reduce subclinical inflammation . The aim study ass underlie mechanisms clinical molecular level long-term efficacy safety pioglitazone NASH multiethnic cohort subject ( predominantly Hispanics , Caucasians African-Americans - common ethnic group locally ) examine response include patient normal glucose tolerance , impair glucose tolerance establish type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>University Texas H.S.C . San Antonio Pioglitazone Non-Alcoholic Steatohepatitis Trial ( UTHSCSA NASH Trial )</brief_title>
	<detailed_description>NASH disease characterize elevated plasma aminotransferases histopathological change liver characterize hepatocellular steatosis , chronic inflammation perisinusoidal fibrosis . NASH affect ( ~30-40 % ) obese type 2 diabetic subject . While pathogenesis NASH poorly understand , consensus insulin resistance associate abnormality lipid metabolism play key role development liver fat accumulation . Insulin resistance nonalcoholic steatohepatitis frequently associate chronic hyperinsulinemia , hyperglycemia , excessive supply plasma free fatty acid liver . This turn promote hepatic lipogenesis . Pioglitazone , thiazolidinedione ( TZD ) , reverse abnormality ameliorate insulin resistance adipose tissue , liver muscle . TZDs decrease excessive ectopic triglyceride accumulation liver muscle , reduce visceral fat , redistribute fat subcutaneous adipose store . We show proof-of-concept 6-month study pioglitazone safe effective treatment T2DM . Patients nonalcoholic steatohepatitis also characterize low plasma adiponectin level . Thiazolidinediones increase plasma adiponectin level , may activate AMP-activated protein kinase , stimulate hepatic/muscle fatty acid oxidation , inhibit hepatic fatty acid synthesis NASH nonalcoholic steatohepatitis . Thiazolidinediones also antiinflammatory effect believe value therapy NASH . In order evaluate hypothesis , investigator treat 36 month group patient impair ( IGT ) glucose tolerance T2DM patient recruit University Hospital medical school clinic newspaper add target San Antonio South Texas geographical area , pioglitazone randomize , double-blinded , placebo-controlled trial . The primary endpoint liver histologic response assess liver biopsy perform 18 36 month treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Be able communicate meaningfully investigator legally competent provide write informed consent . 2 . Age range 18 70 year ( inclusive ) . 3 . Female patient must nonlactating must either least one year postmenopausal , use adequate mechanical contraceptive precaution ( i.e . intrauterine device , diaphragm spermicide , condom spermicide ) , surgically sterilize ( i.e . bilateral tubal ligation , bilateral oophorectomy ) . Female patient undergone hysterectomy eligible participation study . Female patient ( except patient undergone hysterectomy bilateral oophorectomy ) eligible negative pregnancy test throughout study period . Patients oral contraceptive hormonal implant exclude ( patch acceptable deliver much low estrogen systemically ) . 4 . Participants must follow laboratory value : Hemoglobin ≥ 12 gm/dl male , ≥ 11 gm/dl female , WBC count ≥ 3,000/mm3 Neutrophil count ≥ 1,500/mm3 Platelets ≥ 100,000/mm3 Albumin ≥3.0 g/dl Serum creatinine ≤ 1.8 mg/dl Creatinine phosphokinase ≤ 2 time upper limit normal AST ALT ≤ 3.0 time upper limit normal Alkaline phosphatase ≤ 2.5 time upper limit normal 5 . A diagnosis NASH liver biopsy perform within past 6 month , 1 . Any cause chronic liver disease NASH ( restrict alcohol drug abuse , medication , chronic hepatitis B C , autoimmune , hemochromatosis , Wilson 's disease , alpha1antitrypsin deficiency ) . 2 . Any clinical evidence history ascitis , bleed varix , spontaneous encephalopathy . 3 . Current history alcohol abuse ( alcohol consumption great 20 gram ethanol per day ) . 4 . Prior surgical procedure include gastroplasty , jejunoileal jejunocolic bypass . 5 . Prior exposure organic solvent carbon tetrachloride . 6 . Total parenteral nutrition ( TPN ) within past 6 month . 7 . Subjects type 1 diabetes mellitus . 8 . Patients chronic medication know adverse effect glucose tolerance level unless patient stable dose agent 4 week entry study . Patients estrogens hormonal replacement therapy , tamoxifen , raloxifene , oral glucocorticoid chloroquine exclude . 9 . Patients history clinically significant heart disease ( New York Heart Classification great grade II ) , peripheral vascular disease ( history claudication ) , diagnose pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) . 10 . Patients severe osteoporosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Pioglitazone</keyword>
</DOC>